Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis

S I Labidi-Galy*, M Rodrigues, J L Sandoval, J E Kurtz, F Heitz, A M Mosconi, I Romero, U Denison, S Nagao, I Vergote, G Parma, T J Nøttrup, E Rouleau, G Garnier, A El-Balat, C Zamagni, C Martín-Lorente, E Pujade-Lauraine, A Fiévet, I L Ray-Coquard

*Corresponding author for this work

Fingerprint

Dive into the research topics of 'Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science